Ensol Biosciences Statistics

Total Valuation

Ensol Biosciences has a market cap or net worth of KRW 130.22 billion.

Market Cap	130.22B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Ensol Biosciences has 10.88 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	10.88M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	19.24%
Owned by Institutions (%)	4.25%
Float	5.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	186.88
PB Ratio	15.30
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.01, with a Debt / Equity ratio of 0.00.

Current Ratio	9.01
Quick Ratio	8.46
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	-2,544.54

Financial Efficiency

Return on equity (ROE) is -59.14% and return on invested capital (ROIC) is -35.28%.

Return on Equity (ROE)	-59.14%
Return on Assets (ROA)	-31.45%
Return on Capital (ROIC)	-35.28%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +39.42% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+39.42%
50-Day Moving Average	11,008.40
200-Day Moving Average	6,471.60
Relative Strength Index (RSI)	58.35
Average Volume (20 Days)	13,702

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ensol Biosciences had revenue of KRW 537.46 million and -5.40 billion in losses. Loss per share was -644.00.

Revenue	537.46M
Gross Profit	153.05M
Operating Income	-5.17B
Pretax Income	-5.40B
Net Income	-5.40B
EBITDA	-4.77B
EBIT	-5.17B
Loss Per Share	-644.00

Full Income Statement

Balance Sheet

The company has 2.62 billion in cash and 30.00 million in debt, giving a net cash position of 2.59 billion or 238.27 per share.

Cash & Cash Equivalents	2.62B
Total Debt	30.00M
Net Cash	2.59B
Net Cash Per Share	238.27
Equity (Book Value)	6.56B
Book Value Per Share	782.26
Working Capital	2.53B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.65 billion and capital expenditures -142.78 million, giving a free cash flow of -4.80 billion.

Operating Cash Flow	-4.65B
Capital Expenditures	-142.78M
Free Cash Flow	-4.80B
FCF Per Share	-440.84

Full Cash Flow Statement

Margins

Gross Margin	28.48%
Operating Margin	-961.08%
Pretax Margin	-1,005.43%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-892.34%

Dividends & Yields

Ensol Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-5.38%
FCF Yield	-3.68%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ensol Biosciences has an Altman Z-Score of -7.18. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.18
Piotroski F-Score	n/a